Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 20Breast 9Gastrointestinal 5Thoracic 3Genitourinary 2Dermatologic 2Head & Neck 1

Conditions

Prostatic Neoplasms 3Testicular Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Renal Insufficiency 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Failure 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × veliparib × Genitourinary × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡